Abstract:Myelodysplastic Syndrome (MDS) represents a group of clonal hematopoietic disorders characterized by ineffective hematopoiesis and morphological dysplasia. Chromosomal instability is a prominent biological feature of MDS, with over 50% of patients with MDS harboring chromosomal abnormalities or complex karyotypes (CK). The mechanisms underlying mitotic and chromosomal defects associated with MDS remain elusive. In recent years, most studies have focused on the associations of TP53 mutation or deactivation with CK (Bernard et al, Nat Med 2020). Hitherto, besides TP53, few genes were reported associated with cytogenetic aberration in MDS (Bernard et al, Nat Med 2020). To fill this knowledge gap, RNA-Seq was conducted to find the CK-associated transcriptional factors and showed that ONECUT3 is significantly upregulated in MDS with CK, independent of TP53 mutation. Intriguingly ONECUT3 predicted poor survival of MDS patients. Our work indicates that ONECUT3 overexpression gave rise to multinucleated variants and complex karyotype in both TP53-KO MEF and TP53-WT MEF. Mechanistically, overexpressed ONECUT3 transcriptionally activated INCENP and CDCA8 through the direct binding to unique genomic regions, which was performed by RNA-seq and ChIP-seq concurrently. Upregulations of INCENP and CDCA8 induced the assembly of chromosome passenger complex (CPC) that were accumulated in addition to cell equator and midbody during the mitotic phases, consequently causing cytokinesis failure and defective chromosome segregation. As ONECUT3-OE cells attenuated chemo-sensitivity, we explored whether the compounds targeting the ONECUT3-CPC axis could alleviate chemoresistance. Homeobox domain was identified to function as the DNA binding by domain-deleted mutants and structural modeling (AlphaFold - DeepMind). One novel lead-compound C5484617 was later identified by protein structure-based drug virtual screening, to specifically target ONECUT3 and synergically re-sensitize the hypomethylating reagents in MDS with minimized cytotoxicity. In summary, the current study demonstrated that CK-associated TF ONECUT3 upregulates the CPC components in MDS, leading to mitotic defects and decreasing chemo-sensitivity. The Aurora B inhibitor (Barasertib) and a lead compound (C5484617) could help increase the sensitivity of MDS cells to HMA. Our findings are mechanistically significant and of great clinical relevance. The present investigation provides the foothold for further studies to identify novel approaches for MDS patients with limited therapeutic options. Moreover, our findings may be implemented for other cancer types, given that CK/genomic instability is a hallmark of cancer. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability

Pharmacological Targeting of MYC-regulated IRE1/XBP1 Pathway Suppresses MYC-driven Breast Cancer

The Transcriptional Factor ONECUT3 is a Driver and Therapeutic Target for Complex Karyotype MDS

Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN -amplified neuroblastoma

Epigenetic CRISPR Screens Identify Npm1 as a Therapeutic Vulnerability in Non–Small Cell Lung Cancer

Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters

Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability

Loss of nuclear envelope phosphatase CTDNEP1 drives aggressive medulloblastoma by triggering MYC amplification and genomic instability

Identification of MYC synthetic lethal genes and networks

N-myristoyltransferase-1 is necessary for lysosomal degradation and mTORC1 activation in cancer cells

USP29 coordinates MYC and HIF1α stabilization to promote tumor metabolism and progression

USP29 coordinates MYC and HIF1 stabilization to promote tumor metabolism and progression

Epigenetic Drug Library Screening Reveals Targeting DOT1L Abrogates NAD+ Synthesis by Reprogramming H3K79 Methylation in Uveal Melanoma

MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent

Molecular Pathways: Targeting MYC-induced Metabolic Reprogramming and Oncogenic Stress in Cancer.

Cytosolic ME1 Integrated with Mitochondrial IDH2 Supports Tumor Growth and Metastasis.

Inhibition of c-MYC-miRNA 19 Pathway Sensitized CML K562 Cells to Etoposide via NHE1 Upregulation

Synergistic Targeting of CHK1 and Mtor in MYC-driven Tumors.

Targeting the nucleic acid oxidative damage repair enzyme MTH1: a promising therapeutic option

Therapeutic Targeting of YY1/MZF1 Axis by MZF1-uPEP Inhibits Aerobic Glycolysis and Neuroblastoma Progression

Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy